If you, loved one, or a buddy are considering submitting claims from the diabetes medication Onglyza (saxagliptin) for inducing health complications which include heart failure or departure, then our attorneys are more than happy to offer you the legal assistance needs for your case.
Onglyza is a DPP-4 inhibitor, the kind of drugs made to reduce glucose levels and inhibit diabetic complications in adults who have type 2 diabetes.
The FDA (Food and Drug Administration) says that Onglyza users may have a substantial risk of developing congestive heart failure. In a recent FDA advisory committee meeting, it was passed that the tagging used on Onglyza be upgraded with clear warnings about the risk of developing heart failure. It was a warning that was not included the drug’s labels previously.
For those who, loved one, or comparative took Onglyza and endured heart failure, or your loved one died, you may have grounds for a Los Angeles Onglyza lawsuit. Know that AstraZeneca is a massive company and has a group of reliable Mass Tort attorneys representing its interests when the company is slapped with lawsuits.
What Is Onglyza?
Januvia is just another medication, such as Onglyza, that’s used to treat type 2 diabetes. With the increase in insulin levels, the body can process glucose (sugars) and ensure they are kept within the normal selection.
FDA approved using Onglyza after reviewing the outcomes of eight clinical trials done by manufacturers AstraZeneca Pharmaceuticals LP. The trial included a safety study meant to prove that Onglyza was not associated with any substantial risk of cardiovascular disease.
However, recent analyses of the outcomes of a clinical trial on Onglyza done by FDA experts found that concerning issues that connected the medicine to heart disease risks. The trial (the SAVOR research ), which was sponsored by AstraZeneca, had over 16,000 participants. The participants had a history or prone to developing cardiovascular disease. Some of them were given Onglyza, and others obtained a placebo.
The researchers monitored the participants’ health advancement for approximately two years. The results showed many of the patients who used Onglyza were hospitalized for heart failure than those who obtained Placebo. The Onglyza users have a 27% higher risk of cardiovascular disease, heart failure, or associated complications.
The results required stricter scrutiny on the medication by the FDA.
Cardiovascular disease is one of the leading health problems that result in the death of both women and men in the USA. The CDC claims there are almost 610,000 deaths attributed to cardiovascular disease yearly.
It’s a kind of cardiovascular disease where the body gets an insufficient supply of blood. Therefore, less oxygen to its organs, thereby crippling their collective function. If not treated, heart failure grows and leads to deadly health complications with fatal consequences.
For people that have type 2 diabetes and are using Onglyza, the connection between their health issues and the drug is alarming. The FDA began an investigation procedure into the drug and how it increases the probability of heart failure; that can be after increased concerns across the United States. The analysis found stressing problems that resulted in additional warnings of heart failure risk linked with the usage of Onglyza in addition to Kombiglyze XR.
Is There A Link Between Onglyza And Pancreatic Cancer?
Because of how Onglyza stimulates the pancreas to release insulin, that is why the medication was linked to the consumers facing a potential gain in the chance of pancreatitis and pancreatic cancer.
A study was performed in 2013 that focused on how DDP-4 inhibitors affected the pancreas found that participants who had type 2 diabetes and obesity have been using Onglyza have a higher chance of using an enlarged pancreas. They also have an elevated probability of getting precancerous cellular changes in their own pancreas, suggesting a significant probability of developing pancreatic cancer. According to the research, it was also discovered that tumors (precancerous growths) are highly likely to require surgical interventions, and the patients using medication like Onglyza revealed a higher chance of need pancreatic surgery.
The FDA hauled another drug safety alert in March of 2013, saying it had been examining findings of a research that indicated the substantial probability of pancreatitis and precancerous cellular changes in individuals who were using incretin mimetic to take care of their own type 2 diabetes. Among the medications listed as incretin mimetics were Nesina, Januvia, Onglyza, and Byetta.
A later study conducted in 2014 in which researchers examined data from a major clinical trial on Onglyza found no signs of pancreatic cancer or the possibility of pancreatitis. They, nevertheless, recommended further research to make certain they get conclusive findings that indicate pancreatic security regarding using incretin mimetics.
Is Onglyza Linked To Cancer?
Victoza, an incretin mimetic that shares similarities with Onglyza, was discovered to cause malignant thyroid cancer as well as acute pancreatitis in rodents which were given the medication in”clinically relevant” dosages. In June 2011, the FDA issued a safety warning saying the probability of thyroid cancer in the use of Victoza.
No recall was announced, and it is unlikely for you to be issued anytime soon. The recalls seem unforthcoming, yet the reality of coronary failure, cancers, and other possibly deadly health issues cannot be overlooked or swept under the carpet. Vioxx was a medicine that was recalled due to causing strokes and heart attacks, among other cardiovascular concerns.
The same fate is expected of Onglyza along with other incretin mimetics found to increase the risk of heart failure. But it appears that the only significant step taken for these drugs with such serious side effects would be to require that the producers include extra security warnings in their products’ labels. You may come across a”black box” warning at the cap of the drug’s labeling.
Drug harm lawsuits are rarely filed as”class actions,” whereby a few plaintiffs will represent the others that have cases against a drug business. Instead, you will fill such an issue individually.
Back in January 2018, the U.S Judicial Panel on Multidistrict Litigation ordered the”consolidation” of existing lawsuits filed against Kombiglyze and Onglyza in the U.S District Court for the Eastern District of Kentucky. By May 2018, there were around 100 of these cases that shaped consolidated litigation called the MDL 2809. Other suits are still pending the California State Court.
Some of the most notable negative health issues associated with the use of Onglyza include:
- Heart failure
- Kidney problems
- Thyroid cancer
- Pancreatic cancer
Besides the acute side effects Mentioned Previously, Onglyza can also be linked to the following mild to moderate health risk:
- Urinary tract infections
- Rashes and Infection
Could Lawsuit Against Onglyza Be Filed Despite No FDA Recall?
But this directive has many asking why the warning was not included when the item was released ten decades ago.
And when this is the current state of affairs, then it means lots of the patients who took Onglyza within the past decade were unaware of the possible health risk.
The legislation stipulates that drug makers should be responsible for ensuring the public is informed before they release a product into the market. It makes them accountable for any negative outcomes and functions to safeguard the general public from unnecessary health problems.
And as per the legislation, patients who took Onglyza and suffered heart failure can find compensation because the pharmaceutical companies making the drug fail to provide the public with sufficient security warnings about this kind of probable outcome.
Get Help From Our Attorneys For Your Los Angeles Onglyza Lawsuit
In the event that you or a loved one employed Onglyza and endured heart failure, hospitalization, or your relative died due to using the medication, our dedicated class action lawyers are here to assist. We have represented different individuals from across the nation. Thus, we’ve got a profound comprehension o how pharmaceuticals such as Bristol Meyers Squibb and AstraZeneca are expected, by legislation, to ensure physicians and patients are fully conscious of the risk connected with the use of their drugs. Failure to do so implies that these manufacturers are liable for the harm that people using their medications suffer.
We’ve dealt with cases linked to Onglyza and also have a deep comprehension of its flaws. Thus, we are your very best bet if you would like to face the makers of Onglyza and triumph. Contact our law offices now at 855-938-0980 for a free consultation, case review, and find out more about your rights.